MAAT INDEX

CLAIM #22667 · EMR (EMR) · 2024Q1 earnings call · Feb 7, 2024 · due Jun 30, 2029

But right now, we're focused on executing the synergies by year 3. If we find good investment opportunities, we'll make that because I think 31% is the target we've set, and we feel pretty comfortable getting there.

Ram Krishnan · COO

PENDING
graded after results covering Jun 30, 2029 are reported

How to check this claim

Look at: Segment EBITDA margin (or comparable profitability margin metric referenced as the '31% target')

It came true if: Reported margin >= 31%

Where: Company financial disclosures (10-K/10-Q segment reporting or investor presentations) by year 3 post-transaction

Verify independently

SEC filings for EMR · Claim quote is verbatim from the 2024Q1 earnings call.